Fluvastatin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Mixed Dyslipidemia

Conditions

Mixed Dyslipidemia, Hypercholesterolemia

Trial Timeline

Jun 1, 2005 → Apr 1, 2006

NCT ID

NCT00136799

About Fluvastatin

Fluvastatin is a phase 3 stage product being developed by Novartis for Mixed Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00136799. Target conditions include Mixed Dyslipidemia, Hypercholesterolemia.

What happened to similar drugs?

2 of 16 similar drugs in Mixed Dyslipidemia were approved

Approved (2) Terminated (2) Active (12)

✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved

🔄olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3

🔄Lurasidone + PlaceboSumitomo PharmaPhase 3

🔄MK-0524A + Atorvastatin + SimvastatinMerckPhase 3

🔄Inclisiran + Matching Placebo for InclisiranNovartisPhase 3

✅TegaserodNovartisApproved

🔄Atorvastatin + EvolocumabAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01045512	Phase 2	Terminated	Oct 1, 2009	Sep 1, 2014	Aging
NCT00136799	Phase 3	Completed	Jun 1, 2005	Apr 1, 2006	Mixed Dyslipidemia
NCT00125125	Approved	Completed	May 1, 2005	Dec 1, 2005	Dyslipidemia
NCT00138528	Approved	Completed	Oct 1, 2004	Feb 1, 2006	Metabolic Syndrome
NCT00171262	Approved	Completed	Aug 1, 2004	Jun 1, 2007	Dyslipidemia
NCT00171275	Approved	Completed	Nov 1, 2003	—	Coronary Disease
NCT00176410	Phase 2	UNKNOWN	Jan 1, 2003	Dec 1, 2009	Aortic Valve Stenosis
NCT00171236	Phase 3	Completed	Oct 1, 2001	Mar 1, 2005	Heterozygous Familial Hypercholesterolemia
NCT00565474	Approved	Completed	Sep 1, 2001	—	Graft Vasculopathy

Competing Products

20 competing products in Mixed Dyslipidemia

See all competitors

Product	Company	Stage	Hype Score
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	43
olanzapine + lithium + valproate + carbamazepine	Eli Lilly	Phase 3	40
Lurasidone + Placebo	Sumitomo Pharma	Phase 3	40
MK-0524A + Atorvastatin + Simvastatin	Merck	Phase 3	40
Inclisiran + Matching Placebo for Inclisiran	Novartis	Phase 3	40
Tegaserod	Novartis	Approved	43
Atorvastatin + Evolocumab	Amgen	Phase 3	40
Evolocumab + Atorvastatin + Placebo to Evolocumab + Placebo to Atorvastatin	Amgen	Phase 3	40
Blinatumomab in combination with donor lymphocyte infusion	Amgen	Phase 2	27
Evolocumab + Atorvastatin	Amgen	Phase 3	40
Evolocumab + Standard of Care	Amgen	Phase 3	40
torcetrapib/atorvastatin + atorvastatin	Pfizer	Phase 3	32
Bococizumab + Placebo	Pfizer	Phase 3	32
tafamidis	Pfizer	Pre-clinical	26
IBI306 + placebo + placebo + IBI306	Innovent Biologics	Phase 3	47
KarXT	Bristol Myers Squibb	Phase 3	47
KarXT	Bristol Myers Squibb	Phase 3	47
Gemcitabine + Oxaliplatin	Sanofi	Phase 2	35
XL765 (SAR245409) + Temozolomide	Sanofi	Phase 1	29
SAL003 140 mg + Placebo	Shenzhen Salubris Pharmaceuticals	Phase 3	40